Dyslipidemia: Reading Cholesterol Beyond the Total

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Key takeaway:

Dyslipidemia blood testing uses eight markers—LDL, HDL, triglycerides, ApoB, LDL-P, HDL-P, and particle size—to assess atherogenic risk beyond total cholesterol. ApoB (ideally <90 mg/dL) and LDL-P (optimal <1000 nmol/L) are associated with more precise cardiovascular risk assessment than LDL alone. This comprehensive panel may help support precision treatment decisions by linking lipoprotein particle exposure to atherosclerosis and metabolic health.

Read more →

Understand what your heart cardiovascular testing results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

Dyslipidemia and the particles that carry cholesterol

Dyslipidemia biomarkers are the measurable fats and the proteins that carry them in blood, revealing how your body transports and disposes of lipids every day. Core measures capture the main cargo (cholesterol and triglycerides) and the vehicles that move it—low-density, high-density, and very-low-density lipoproteins (LDL, HDL, VLDL). The liver builds and recycles most of these particles, while the intestine contributes after meals (chylomicrons). As VLDL sheds triglyceride, it becomes LDL, a particle that can enter artery walls; HDL helps ferry cholesterol back to the liver (reverse cholesterol transport). Protein “tags” on particles add precision: apolipoprotein B reflects the number of artery-entering particles (apoB-containing lipoproteins), apolipoprotein A-I reflects major HDL scaffolding (apoA-I), and a genetically influenced variant, lipoprotein(a), adds a pro-atherogenic component (Lp(a)). Together, these tests map the balance between lipid delivery, storage, and clearance. They enable clinicians to identify harmful traffic patterns in the bloodstream, personalize nutrition and medication choices, and track whether the body’s lipid flow is moving toward arterial safety.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Reading an advanced lipid panel

Dyslipidemia testing reveals how your body packages and traffics fats through the bloodstream—information that touches the heart and vessels, liver fat handling, pancreatic safety, hormone building blocks, and even inflammation. It is less about one number and more about the number and nature of lipoprotein particles that contact artery walls. Common cut points help frame risk. LDL is best kept toward the lower end (often desirable below 100), while HDL is more protective at the higher end (≥60; low is <40 in men and <50 in women). Triglycerides are safest toward the lower end (normal <150). ApoB, a direct count of atherogenic particles, is ideally low (often <90). LDL-P, another particle count, is optimal toward the lower end (commonly <1000). HDL-P reflects the quantity of HDL particles; higher tends to be favorable. LDL size is categorized as larger (pattern A) versus smaller (pattern B), with larger being better. HDL size generally tracks benefit in the mid-to-larger range. When values are low, the meaning differs by marker. Low LDL, ApoB, and LDL-P indicate fewer artery-penetrating particles; if extremely low, they may reflect hyperthyroidism, malabsorption, or rare genetic variants, sometimes with fatigue or fat-soluble vitamin issues. Very low triglycerides can be normal or reflect hyperthyroidism or undernutrition. Low HDL and HDL-P suggest impaired reverse cholesterol transport, often seen with insulin resistance. In pregnancy, lipids rise physiologically; in children and teens, low HDL and high triglycerides often signal early metabolic risk. Big picture: these markers map energy transport and vascular exposure. They integrate with glucose metabolism, thyroid and liver function, inflammation, and genetics—helping forecast atherosclerosis, pancreatitis risk (when triglycerides are very high), and long-term cardiovascular outcomes.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

What a lipid workup can and can't settle

Dyslipidemia blood testing provides a window into how your body manages fats, which are essential for energy, hormone production, cell structure, and brain function. Imbalances in blood lipids can disrupt cardiovascular health, metabolism, and even immune and reproductive systems. At Superpower, we measure LDL, HDL, triglycerides, ApoB, LDL-P, HDL-P, LDL size, and HDL size to give a comprehensive view of your lipid profile. LDL (low-density lipoprotein) is often called “bad cholesterol” because high levels can deposit cholesterol in artery walls, increasing cardiovascular risk. HDL (high-density lipoprotein), or “good cholesterol,” helps remove cholesterol from the bloodstream. Triglycerides are the main form of fat in the blood, reflecting how your body stores and uses energy. ApoB is a protein found on LDL and other atherogenic particles, serving as a direct count of particles that can contribute to plaque buildup. LDL-P and HDL-P measure the number of LDL and HDL particles, while LDL size and HDL size describe the average size of these particles, which can influence their behavior in the body. A stable and healthy lipid profile—characterized by optimal levels and particle sizes—supports resilient blood vessels, efficient energy use, and balanced hormone production. Dyslipidemia, or abnormal lipid levels, can signal increased risk for atherosclerosis, metabolic syndrome, and other systemic imbalances. Interpretation of these biomarkers can be influenced by factors such as age, sex, pregnancy, acute illness, certain medications, and laboratory methods. These variables are important to consider when assessing lipid health.

Frequently Asked Questions

References

  1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, ... Wiklund O (2020). 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *European Heart Journal*, *41*(1), 111-188. https://doi.org/10.1093/eurheartj/ehz455
  2. Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference BA (2019). Apolipoprotein B particles and cardiovascular disease: A narrative review. *JAMA Cardiology*, *4*(12), 1287-1295. https://doi.org/10.1001/jamacardio.2019.3780
  3. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, ... Catapano AL (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *European Heart Journal*, *38*(32), 2459-2472. https://doi.org/10.1093/eurheartj/ehx144
  4. Emerging Risk Factors Collaboration. (2009). Major lipids, apolipoproteins, and risk of vascular disease. *JAMA*, *302*(18), 1993-2000. https://doi.org/10.1001/jama.2009.1619
  5. Garg R, Rustagi T (2018). Management of hypertriglyceridemia induced acute pancreatitis. *BioMed Research International*, *2018*, 4721357. https://doi.org/10.1155/2018/4721357

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Membership 1
1 / 4

Your membership starts here

Annual 100+ biomarker panel

  • Data dashboard and digital twin
  • Upload past labs and connect wearables
  • Personalized health protocol
  • 24/7 care team access
  • AI companion for all health questions
  • Marketplace with additional solutions
$199
/year*Billed annually
Get started
HSA/FSA eligibleCancel anytimeResults in a week

*Pricing may vary for members in New York and New Jersey